Skip to main content
OpenTrials
Completed

NCT Number: NCT07076758

Correlation Between Serum Copper and Cardiac Enzymes in Acute Myocardial Infarction

This study aims to investigate the correlation between serum copper levels and cardiac enzymes in patients with acute myocardial infarction (AMI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag University

Sohag, 82511, Egypt

About this study

Acute myocardial infarction (AMI) is one of the most serious types of coronary artery disease (CAD). In CAD, coronary blood flow is drastically reduced or interrupted, causing severe myocardial ischemia or necrosis.

Cardiac troponin I (TNI), creatine kinase (CK), and creatine kinase MB (CK-MB) are the most commonly used biomarkers for AMI clinical diagnosis. Among them, cardiac troponin is a highly specific biomarker for the diagnosis of AMI. However, the sensitivity is not good in the first few AMI hours, and false-positive values may occur in severe heart failure, arrhythmia, and myocarditis.

Copper is vital in multiple enzymes necessary for antioxidant protection, such as Superoxide dismutases (SOD) and ceruloplasmin. SOD is an enzyme that changes superoxide radicals into hydrogen peroxide, whereas ceruloplasmin is an antioxidant protein that aids in eliminating free radicals.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old.
  • Both sexes.
  • Patients with acute myocardial infarction (AMI). AMI are defined as patients complaining of typical continuous chest pain for more than 30 min: ST-segment elevation of more than 0.1 mV in two or more successive leads or ST-segment depression of more than 0.1 mV in two or more successive leads monitored by a standard 12-lead ECG and rise of either creatine kinase (CK) or MB fraction of creatine kinase (CKMB) to greater than twice the normal level or elevation of troponin I [cardiac troponin T (cTnT)] more than or equal to 0.1 ng/ml

Exclusion criteria

  • Patients with insufficient clinical information.
  • Passed time MI (if patients presented with symptoms that lasted >24 h).
  • Cardiogenic shock.
  • Chronic kidney disease.
  • Chronic liver cell failure.
  • Significant valvular heart disease.
  • Hematological disease.
  • Malignancy.
  • Severe liver or renal disease.
  • Systemic inflammatory disease.
  • Active infection.
  • Autoimmune disease.
  • Patients on steroids whatever the cause is.

Treatment and study plan

Transthoracic Echocardiography

Other

Transthoracic echocardiography will be done for all patients during their cardiac care unit stay including two-dimensional and color Doppler echocardiography studies. It will be performed in the left lateral position using the parasternal and apical transducer positions. All studies will be technically adequate for scoring endocardial regional wall motion. The following views will be obtained: long-axis parasternal, short-axis parasternal, apical four chamber, apical two-chamber and apical five-chamber views. All the measurements taken will be according to the criteria of the American Society of Echocardiography

Primary outcomes

  1. Serum copper level

    Time frame: Immediately after echocardiography (Up to 1 hour)

    Serum copper level will be recorded.

Secondary outcomes

  1. Correlation between copper zinc and cardiac enzyme

    Time frame: Immediately after echocardiography (Up to 1 hour)

    Correlation between copper zinc and cardiac enzyme will be done.

  2. Creatine kinase

    Time frame: Immediately after echocardiography (Up to 1 hour)

    Creatine kinase level will be recorded.

  3. MB fraction of creatine kinase

    Time frame: Immediately after echocardiography (Up to 1 hour)

    MB fraction of creatine kinase will be recorded.

  4. Cardiac troponin T

    Time frame: Immediately after echocardiography (Up to 1 hour)

    Cardiac troponin T will be recorded.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 22, 2025
Registry last updated
Jul 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.